Medifast Is Running The Same Playbook, And I Have The Same Concerns

Medifast (MED) maintains a strong, cash-heavy balance sheet and trades near liquidation value, but its business model remains uninspiring amid GLP-1 disruption. Q3 2026 revenue declined 19.4% YoY to $72M, with active earning coaches down 47%, though average revenue per coach increased. Management transition and Steamboat Capital's activist involvement signal board-level changes, but the core product and MLM-style distribution remain unchanged.

Seeking Alpha • Oct 28, 2026

Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises

MED tops Q3 earnings expectations as coach productivity jumps 54.1% and margins expand, despite declining revenues and a shrinking coach network.

Zacks Investment Research • Oct 27, 2026

What Medifast (MED) Said on Its Q3 Earnings Call

Medifast NYSE: MED reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management said revenue was within its guidance range and marked a fourth consecutive quarter in which sales stabilized around the mid-$70 million range.

MarketBeat • Oct 26, 2026

Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript

Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript

Seeking Alpha • Oct 26, 2026

Medifast Announces Third Quarter 2026 Financial Results

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for the third quarter ended September 30, 2026. Third Quarter 2026 Revenue: $72.0 million, with revenue per active earning coach of $7,064 Independent active earning coaches of 10,200 Net loss of $17.5 million (non-GAAP adjusted net loss of $2.1 million) Loss per diluted share ("EPS") of $1.57 (non-GAAP a.

Business Wire • Oct 26, 2026

Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates

Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.21 per share a year ago.

Zacks Investment Research • Oct 26, 2026

Medifast Q3 Earnings on the Horizon: Key Insights for Investors

MED's Q3 results are likely to face pressure from GLP-1 adoption, shrinking coach numbers and lower sales, while strategic initiatives may offer some support.

Zacks Investment Research • Oct 23, 2026

Why Is Weight Loss Different During Menopause? Common Myths Debunked

Myth: Menopause weight gain is inevitable. Truth: Acceleration is not inevitable.

GlobeNewsWire • Oct 15, 2026

Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2026

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, will announce financial results for the quarter ended September 30, 2026 on Monday, October 26, 2026, before market open. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Offic.

Business Wire • Oct 14, 2026

New Strong Buy Stocks for October 14th

NATL, BGC, CCNE, FRME and UVSP have been added to the Zacks Rank #1 (Strong Buy) List on October 14, 2026.

Zacks Investment Research • Oct 14, 2026